Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies - 08/07/21
, David Amato, DO b, William Huster, PhD b, Clement Ojeh, PhD c, Abby S. Van Voorhees, MD dAbstract |
Background |
The National Psoriasis Foundation (NPF) published treatment targets for US patients with plaque psoriasis. However, data are lacking on how well existing therapies help achieve these goals.
Objective |
To examine the ability of an interleukin 17 inhibitor, ixekizumab, in achieving these treatment targets.
Methods |
Post hoc analysis was performed on pooled data from 4 phase III clinical trials assessing ixekizumab for plaque psoriasis: the UNCOVER-1, -2, and -3 trials and the IXORA-S trial. Treatment response was evaluated using the NPF-defined acceptable response (affected body surface area [BSA] of 3% or less or BSA improvement of 75% or higher at 12 weeks of treatment) and target response (BSA of 1% or less at 12 weeks and every 6 months thereafter).
Results |
In the UNCOVER trials (n = 2701), acceptable and target response rates at week 12 were 73.9% and 51.8% with ixekizumab 80 mg every 2 weeks, 35.7% and 14.9% with etanercept 50 mg, and 3.0% and 0.6% with placebo, respectively. In the IXORA-S trial (n = 302), acceptable and target response rates at week 12 were significantly higher with ixekizumab every 2 weeks versus ustekinumab (acceptable response 68.4% vs 38.6%, P < .0001; target response 50.7% vs 24.1%, P < .0001).
Limitations |
Data were from controlled studies and may not reflect real-world practice.
Conclusion |
The majority of patients treated with ixekizumab in 4 phase III clinical trials achieved NPF, patient-centered treatment targets.
Le texte complet de cet article est disponible en PDF.Key words : etanercept, interleukin 17, ixekizumab, National Psoriasis Foundation, pooled analysis, psoriasis, treatment goals
Abbreviations used : BSA, NPF, PASI, sPGA
Plan
| Funding sources: Supported by Eli Lilly and Company. |
|
| Presentation: “Achievement of the National Psoriasis Foundation Treatment Targets Among Patients in Ixekizumab Clinical Trials: Analysis of Pooled UNCOVER Results” was presented at the National Psoriasis Foundation 2017 Research Symposium, Chicago, Illinois, August 3-5, 2017. |
|
| Conflicts of interest: Dr Armstrong has served as an investigator and/or advisor to AbbVie, BMS, Celgene, Janssen, Novartis, Eli Lilly and Company, Leo Pharma, Regeneron, Sanofi, and Ortho Dermatologics. Dr Amato is a shareholder and former employee of Eli Lilly and Company. Drs Huster and Ojeh were employees but retired from Eli Lilly and Company. Dr Van Voorhees has received honoraria for consulting and/or participating in the advisory boards for Dermira, Novartis, Allergan, Celgene, AbbVie, DermTech, Pfizer, AstraZeneca, Corrona, and Valeant; she also served as an investigator for Celgene, Lilly, and Corrona. |
|
| IRB approval status: The individual studies were approved by institutional review boards. Reprints not available from the authors. |
Vol 85 - N° 2
P. 330-336 - août 2021 Retour au numéro
Article précédent
- Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis
- Maria C. Schneeweiss, Lourdes Perez-Chada, Joseph F. Merola
- Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
- Hsien-Yi Chiu, Ying-Ming Chiu, Nien-Feng Chang Liao, Ching-Chi Chi, Tsen-Fang Tsai, Chang-Yu Hsieh, Tsu-Yi Hsieh, Kuo-Lung Lai, Tsu-Man Chiu, Nan-Lin Wu, Rosaline Chung-yee Hui, Chaw-Ning Lee, Ting-Shun Wang, Po-Hua Chen, Chao-Chun Yang, Yu-Huei Huang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?